Mechanistic comparison of Levobupivacaine S-enantiomer of bupivacaine that is used as and Ranitidine based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
3
Shared Targets
30%
Jaccard Similarity
25%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Levobupivacaine and Ranitidine share 3 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.300 means 30% of the combined target set is bound by both compounds. The IDF-weighted score of 0.252 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Levobupivacaine and Ranitidine have in common?
Levobupivacaine and Ranitidine share 3 molecular targets with a Jaccard similarity of 30%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Levobupivacaine and Ranitidine be combined?
Levobupivacaine and Ranitidine share 3 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Levobupivacaine or Ranitidine?
Both Levobupivacaine and Ranitidine have substantial PubMed research. View their individual profiles for full evidence scores.